US EditionTrial into puberty blockers for children paused over 'wellbeing concerns'
The UK regulator halted a trial involving 226 children aged 10-15 over safety concerns, including risks of long-term biological harm and consent issues, pending further review.
- A clinical trial on puberty blockers for children has been paused after the Medicines and Healthcare products Regulatory Agency raised safety concerns, including a recommended minimum age limit of 14 due to unquantified risks of long-term harms.
- The MHRA will discuss these concerns with the trial sponsor, King's College London, before recruitment can resume, and the trial will proceed only with expert scientific and clinical approval confirming it is safe and necessary.
- The trial, recommended by the Cass Review, aims to build a better evidence base given the previously weak or poor evidence on benefits of puberty blockers for young people with gender dysphoria, recruiting participants aged 10 to almost 16.
21 Articles
21 Articles
UK Puberty Blocker Trial Halted Over Safety Fears
A controversial NHS-backed trial giving puberty blockers to children as young as eight has been dramatically halted after Britain’s medicines watchdog intervened over safety fears. The Medicines and Healthcare products Regulatory Agency (MHRA) has pressed pause on the Pathways study, warning of potentially “significant” and unquantified long-term harms. Officials are now demanding urgent talks with trial leaders at King’s College London, includi…
UK Puberty Blocker Trial Finally Halted Over Significant Safety Concerns
A shocking NHS-supported trial has now been suspended following officials’ warnings of “significant” long-term harms to young people. The controversial plans aimed to give puberty blockers to children as young as eight-years-old, but the […] The post UK Puberty Blocker Trial Finally Halted Over Significant Safety Concerns first appeared on The Expose.
Sky News UK
Great Yorkshire RadioTrial into puberty blockers for children paused over 'wellbeing concerns'
Recruitment to the study will be postponed until the issues have been resolved with the sponsor, King's College, and it is concluded that it is "both safe and necessary", a spokesperson for the Department of Health and Social Care.
The Independent
The Independent (US)Puberty blockers’ clinical trial paused after concerns from regulator
The MHRA will now discuss the concerns, related to the wellbeing of children and young people with gender dysphoria, with trial sponsor King’s College London next week
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
